Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s112. https://doi.org/10.25251/skin.7.supp.112